Search
for
Sort by
Research 30 of 283
- Cyclin-Dependent Kinase 4/6 Inhibitors and Dermatologic Adverse Events: Results from the EADV Task Force “Dermatology for Cancer Patients” International Study
- Retrospective cohort study of CDK4/6-inhibitor-induced alopecia in breast cancer patients
- Alopecia induced by CDK 4/6 Inhibitors and its Impact on the Quality of Life of Patients with advanced Breast cancer
- Safety and quality of life of CDK4/6 inhibitors therapy for hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer: a multicenter cross-sectional survey in China
- Abemaciclib-Associated Skin, Hair, and Nail Toxicities: A Case Report
- Patient, Oncologist, and Payer Preferences for Adjuvant Endocrine Therapy and CDK4/6 Inhibitor Regimens in Early-Stage Breast Cancer: A Discrete Choice Experiment
- Drug repurposing of cyclin-dependent kinase inhibitors for neutrophilic acute respiratory distress syndrome and psoriasis
- Maternal androgen excess inhibits fetal cardiomyocytes proliferation through RB-mediated cell cycle arrest and induces cardiac hypertrophy in adulthood
- Effect of palbociclib plus letrozole on patient-reported health-related quality of life: extended follow-up of the PALOMA-2 trial
- Patient Preferences: Results of a German Adaptive Choice-Based Conjoint Analysis (Market Research Study Sponsored by Eli Lilly and Company) in Patients on Palliative Treatment for Advanced Breast Cancer
- Approaches to management of endocrine therapy–induced alopecia in breast cancer patients
- Oral minoxidil for late alopecia in cancer survivors
- Hair loss during and after breast cancer therapy
- Cancer-Related Alopecia: From Etiologies to Global Management
- Managing hyperglycemia and rash associated with alpelisib: expert consensus recommendations using the Delphi technique
- Treatment of Chemotherapy Induced Alopecia
- Mechanism-Based Strategies for Prevention of Taxane-Induced Hair Follicle Damage in Cancer Chemotherapy
- Expert consensus for prevention, diagnosis and management of persistent chemotherapy-induced alopecia.
- Poster Presentations at the 28th Joint Meeting of the International Society of Dermatopathology, March 5–6, 2025, Orlando, Florida, USA
- Safety First: A Comprehensive Review of Nutritional Supplements for Hair Loss in Breast Cancer Patients
- Poster Presentations
- Restoration of follicular β-catenin signaling by mesenchymal stem cells promotes hair growth in mice with androgenetic alopecia
- CDK4/6 inhibition mitigates stem cell damage in a novel model for taxane‐induced alopecia
- CDK4/6 plus aromatase inhibitor-induced alopecia in breast cancer patients.
- Hormone receptor positive, HER2 negative metastatic breast cancer: Impact of CDK4/6 inhibitors on the current treatment paradigm
- Impact of CDK4/6 inhibitors on health-related quality of life outcomes in patients with metastatic breast cancer: A systematic review and meta-analysis
- Safety and patient-reported outcomes in patients with hormone receptor-positive, HER2-negative advanced breast cancer treated with CDK4/6 inhibitors in China: A cross-sectional study.
- Retrospective cohort study of CDK4/6-inhibitor-induced alopecia in patients with breast cancer.
- NFATc1 Balances Quiescence and Proliferation of Skin Stem Cells
- Molecular Regulation of Melanocyte Senescence